Eurofins-Cerep SA

Paris Stock Exchange ALECR.PA

Eurofins-Cerep SA EBITDA for the year ending December 31, 2023: USD 10.04 M

Eurofins-Cerep SA EBITDA is USD 10.04 M for the year ending December 31, 2023, a -25.25% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Eurofins-Cerep SA EBITDA for the year ending December 31, 2022 was USD 13.44 M, a 10.15% change year over year.
  • Eurofins-Cerep SA EBITDA for the year ending December 31, 2021 was USD 12.20 M, a 58.53% change year over year.
  • Eurofins-Cerep SA EBITDA for the year ending December 31, 2020 was USD 7.70 M, a 35.52% change year over year.
  • Eurofins-Cerep SA EBITDA for the year ending December 31, 2019 was USD 5.68 M, a 23.22% change year over year.
Key data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)
Market news
SV Wall Street
Paris Stock Exchange: ALECR.PA

Eurofins-Cerep SA

CEO Mr. Damien Vielliard
IPO Date April 12, 2000
Location France
Headquarters Le Bois l'Evêque
Employees 209
Sector Healthcare
Industries
Biotechnology Bitcoin & Crypto Clinical Trials Fintech Investment Banking & Asset Management Pharmaceuticals Rating Agencies Research & Consulting
Description

Eurofins Cerep SA provides various drug discovery services to pharmaceutical and biotechnology companies worldwide. The company's research services include compound management, high-throughput screening, in vitro safety profiling, lead optimization (or SAR) profiling, in vitro ADME profiling, and in vivo PK. It also offers assay design and development services. The company was formerly known as Cerep SA and changed its name to Eurofins Cerep SA in June 2014. Eurofins Cerep SA was founded in 1989 and is based in Vienne, France.

StockViz Staff

February 7, 2025

Any question? Send us an email